

## CURRICULUM VITAE

Name: Donald Bruce Vaupel

Address: Neuropsychopharmacology Section  
National Institute on Drug Abuse  
Addiction Research Center  
P.O. Box 1580  
Baltimore, MD 21224

Date and Place of Birth: August 30, 1942; Hackensack, New Jersey

Education:

- 1960-1964 Wittenberg University, Springfield, Ohio. Received B.A. in Chemistry and Biology in June 1964.
- 1966-1970 University of Kentucky Medical Center. Studied in the laboratory of W. R. Martin and received M.S. degree in Pharmacology in May 1970.
- 1970-1974 University of Kentucky Medical Center. Studied in the laboratory of W. R. Martin and received Ph.D. degree in Pharmacology in May 1974.

Title of Master's Dissertation:

"Facilitation of the Flexor Reflex in the Chronic Spinal Dog by Oxotremorine and its Interaction with Cholinergic, Adrenergic and Serotonergic Blocking Agents."

Title of Doctoral Dissertation:

"The Effects of Norepinephrine, Methoxamine and Tryptamine on Segmental Reflex Activity of the Decerebrate, Acute Spinal Cat."

Professional Experience:

- 1962-1964 Teaching Assistant, Department of Biology, Wittenberg University, Springfield, Ohio.
- 1964-1966 Chemist, Quality Control Laboratory, Lederle Laboratories, Pearl River, New York.
- 1967-1969 Graduate Assistant, Department of Pharmacology, University of Kentucky Medical Center, Lexington, Kentucky.
- 1969-1972 Biological Research Technician, National Institute for Mental Health, Addiction Research Center, Lexington, Kentucky.

- 1972-1984      Pharmacologist, Clinical Neuropharmacology and Whole Animal Pharmacology sections, National Institute on Drug Abuse, Addiction Research Center, Lexington, Kentucky
- 1978-1984      Assistant Adjunct Professor, Department of Pharmacology, University of Kentucky College of Medicine, Lexington, Kentucky.
- 1984-present    Pharmacologist, Neuropsychopharmacology Section, National Institute on Drug Abuse, Addiction Research Center, Baltimore, MD

Related Professional Activities at the Addiction Research Center:

Contributed to the WHO Expert Committee on Drug Dependence twenty-first report (1978), specifically the section presenting techniques for evaluating lysergide-like hallucinogens; helped write and prepare the Animal Care Handbook (1979); prepared a Surgery Handbook (1980); aided in preparing NIDA's medical and scientific review of five agonist/antagonist drugs for the Secretary General, United Nations (1981); reviewed articles for the Journal of Medicinal Chemistry, Psychopharmacology, and Pharmacology Biochemistry and Behavior; serve on the Animal Care Committee (1979 to present).

Professional Societies:

Sigma Xi  
American Society for Pharmacology and Experimental Therapeutics

Invited Lectures at Workshops and Symposia:

NIDA Technical Review on the Psychopharmacology of Hallucinogens, Bethesda, Maryland (1976).

NIDA Technical Review on the Chemistry and Pharmacology of PCP and its Analogues, Rockville, Maryland (1979).

FASEB Symposium on Commonalities in the Properties of Phencyclidine-like Drugs and Opioids, New Orleans, Louisiana (1982).

Joint French-U.S. Seminar on the Chemistry, Pharmacology, Toxicology, Therapy and Drug Abuse Aspects of Arylcyclohexylamines, LaGrande Motte (Montpellier), France (1982).

## BIBLIOGRAPHY

- Vaupel, D. B. and Martin, W. R.: Interaction of oxotremorine with atropine, chlorpromazine, cyproheptadine, imipramine and phenoxybenzamine on the flexor reflex of the chronic spinal dog. *Psychopharmacologia* 30: 13-26, 1973.
- Vaupel, D. B. and Martin, W. R.: Actions of methoxamine and tryptamine and their interactions with cyproheptadine and phenoxybenzamine on cat spinal cord segmental reflexes. *J. Pharmacol. Exp. Ther.* 196: 87-96, 1976.
- Martin, W. R., Sloan, J. W., Vaupel, D. B., Bell, J. A. and Nozaki, M.: Tryptamine in the brain and spinal cord: Its role in the LSD response. In: *Trace Amines and the Brain*, E. Usdin and M. Sandler (eds.), pp. 83-102. New York: Marcel Dekker, 1976.
- Vaupel, D. B., Nozaki, M. and Martin, W. R.: A pharmacologic comparison of 2,5-dimethoxyamphetamine and LSD in the chronic spinal dog. *Drug Alc. Depend.* 2: 45-63, 1977.
- Nozaki, M., Vaupel, D. B. and Martin, W. R.: A pharmacologic comparison of 3,4-methylenedioxyamphetamine and LSD in the chronic spinal dog. *Eur. J. Pharmacol.* 46: 339-349, 1977.
- Nozaki, M., Bell, J. A., Vaupel, D. B. and Martin, W. R.: Responses of the flexor reflex to LSD, tryptamine, 5-hydroxytryptophan, methoxamine, and d-amphetamine in acute and chronic spinal rats. *Psychopharmacology* 55: 13-18, 1977.
- Martin, W. R., Vaupel, D. B., Nozaki, M. and Bright, L. D.: The identification of LSD-like hallucinogens using the chronic spinal dog. Minutes, 39th Meeting, Committee on Problems of Drug Dependence, National Research Council, Cambridge, Mass., pp. 367-380, 1977.
- Vaupel, D. B., Martin, W. R., Bright, L. D. and Nozaki, M.: Single dose and cross tolerance studies of LSD, d-amphetamine,  $\beta$ -phenethylamine and 4-bromo-2,5-dimethoxyamphetamine in the chronic spinal dog. Minutes, 39th Meeting, Committee on Problems of Drug Dependence, National Research Council, Cambridge, Mass., pp. 381-393, 1977.
- Martin, W. R., Vaupel, D. B., Nozaki, M. and Bright, L. D.: The identification of LSD-like hallucinogens using the chronic spinal dog. *Drug Alc. Depend.* 3: 113-123, 1978.
- Vaupel, D. B., Nozaki, M., Martin, W. R. and Bright, L. D.: Single dose and cross tolerance studies of  $\beta$ -phenethylamine, d-amphetamine and LSD in the chronic spinal dog. *Eur. J. Pharmacol.* 48: 431-437, 1978.
- Nozaki, M., Vaupel, D. B., Bright, L. D. and Martin, W. R.: A pharmacological comparison of 3-methoxy-4,5-methylenedioxyamphetamine and LSD in the dog. *Drug Alc. Depend.* 3: 153-163, 1978.

Jasinski, D. R., Gilbert, P. E., Vaupel, D. B., Risner, M. E. and Cone, E. J.: Progress report from the NIDA Addiction Research Center. Minutes, 40th Meeting, Committee on Problems of Drug Dependence, National Research Council, Baltimore, Md., pp. 151-182, 1978.

Martin, W. R., Vaupel, D. B., Sloan, J. W., Bell, J. A., Nozaki, M. and Bright, L. D.: The mode of action of LSD-like hallucinogens and their identification. In: The Psychopharmacology of Hallucinogens, R. C. Stillman and R. E. Willette (eds.), pp. 118-125. New York: Pergamon Press, 1978.

Vaupel, D. B., Nozaki, M., Martin, W. R., Bright, L. D. and Morton, E. C.: The inhibition of food intake in the dog by LSD, mescaline, psilocin, d-amphetamine and phenylisopropylamine derivatives. Life Sci. 24: 2427-2432, 1979.

Jasinski, D. R., Cone, E. J., Gorodetzky, C. W., Risner, M. E., Shannon, H. E., Su, T.-P. and Vaupel, D. B.: Progress report from the NIDA Addiction Research Center. In: Problems of Drug Dependence, 1979 (Proceedings of the 41st Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc.). NIDA Research Monograph Series, No. 27, pp. 61-69, 1980.

Su, T.-P., Cone, E. J., Shannon, H. E. and Vaupel, D. B.: Relative potencies of phencyclidine and analogues in the opiate receptor binding assay: Correlation with relative potencies determined in vivo in mouse and rat. Res. Comm. Substance Abuse 1: 85-98, 1980.

Cone, E. J., Vaupel, D. B. and Buchwald, W. F.: Phencyclidine: Detection and measurement of toxic precursors and analogues in illicit samples. J. Analyt. Toxicol. 4: 119-123, 1980.

Vaupel, D. B. and Cone, E. J.: A pharmacologic comparison between phencyclidine, its precursors, metabolites and a quaternary derivative in the dog. In: Problems of Drug Dependence 1980 (Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc.). NIDA Research Monograph Series, No. 34, pp. 180-186, 1981.

Carroll, F. I., Brine, G. A., Boldt, K. G., Cone, E. J., Yousefnejad, D., Vaupel, D. B. and Buchwald, W. F.: Phencyclidine metabolism: Resolution, structure, and biological activity of the isomers of the hydroxy metabolite, 4-phenyl-4-(1-piperidinyl)cyclohexanol. J. Med. Chem. 24: 1047-1051, 1981.

Jasinski, D. R., Shannon, H. E., Cone, E. J., Vaupel, D. B., Risner, M. E., McQuinn, R. L., Su, T.-P. and Pickworth, W. B.: Interdisciplinary studies on phencyclidine. In: PCP (Phencyclidine): Historical and Current Perspectives, E. F. Domino (ed.), pp. 331-400. Ann Arbor, MI: NPP Books, 1981.

Cone, E. J., Shannon, H., Vaupel, B., Su, T.-P. and McQuinn, R.: A structure activity relationship study of the cyclohexyl and aromatic rings of phencyclidine (PCP). In: Problems of Drug Dependence, 1981 (Proceedings of the 43rd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc.). NIDA Research Monograph Series, No. 41, pp. 126-133, 1982.

Cone, E. J., Vaupel, D. B. and Yousefnejad, D.: Monohydroxymetabolites of phencyclidine (PCP): Activities and urinary excretion by rat, dog and mouse. *J. Pharm. Pharmacol.* 34: 197-199, 1982.

Vaupel, D. B. and Morton, E. C.: Anorexia and hyperphagia produced by five pharmacologic classes of hallucinogens. *Pharmacol. Biochem. Behav.* 17: 539-545, 1982.

Shannon, H. E., McQuinn, R. L., Vaupel, D. B. and Cone, E. J.: Effects of cycloalkyl ring analogs of phencyclidine on behavior in rodents. *J. Pharmacol. Exp. Ther.* 224: 327-333, 1983.

Vaupel, D. B.: Naltrexone fails to antagonize the  $\sigma$  effects of PCP and SKF 10,047 in the dog. *Eur. J. Pharmacol.* 92: 269-274, 1983.

Vaupel, D. B.: Phencyclidine studies in the dog: Pharmacology of PCP, profiles of eight analogues abused by man and the similarity of PCP to the opioid NANM (N-allylnormetazocine or SKF 10,047). In: Phencyclidine and Related Arylcyclohexylamine: Present and Future Applications, J. M. Kamenka, E. F. Domino and P. Geneste (eds.), pp. 347-367. Ann Arbor, MI: NPP Books, 1983.

Gorodetzky, C. W., Cone, E. J., Goldberg, S. R., Herling, S., Risner, M. E., Shannon, H. E. and Vaupel, D. B.: Progress report from the NIDA Addiction Research Center (Preclinical Laboratory), Lexington, Ky. In: Problems of Drug Dependence, 1982 (Proceedings of the 44th Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc.). NIDA Research Monograph Series, No. 43, pp. 85-91, 1983.

Vaupel, D. B., McCoun, D. and Cone, E. J.: Phencyclidine analogues and precursors: Rotarod and lethal dose studies in the mouse. *J. Pharmacol. Exp. Ther.* 230: 20-27, 1984.

Vaupel, D.B., Risner, M.E. and Shannon, H.E.: Pharmacologic and reinforcing properties of phencyclidine and the enantiomers of N-allylnormetazocine in the dog. Submitted for publication.

## ABSTRACTS

- Vaupel, D. B. and Martin, W. R.: A comparison of the effects of methoxamine (M), norepinephrine (Ne) and tryptamine (T) on segmental reflex activity of the acute spinal cat. *Pharmacologist* 13: (2) 254, Fall 1971.
- Vaupel, D. B. and Nozaki, M.: A comparison of the effects of 2,5-dimethoxyamphetamine (DMA) and lysergic acid diethylamide (LSD) in the dog. *Fed. Proc.* 34: 767, 1975.
- Vaupel, D. B., Nozaki, M. and Martin, W. R.: Evaluation of cross tolerance to  $\beta$ -phenethylamine and *d*-amphetamine in LSD tolerant dogs. *Pharmacologist* 18: 128, 1976.
- Martin, W. R., Sloan, J. W., Vaupel, D. B., Bell, J. A. and Nozaki, M.: Tryptamine in the brain and spinal cord: Its role in the LSD response. *Psychopharmacol. Bull.* 12: 31-32, 1976.
- Vaupel, D. B. and Nozaki, M.: The LSD and amphetamine-like actions of 3,4-methylenedioxyamphetamine in the chronic spinal dog. *Fed. Proc.* 36: 1039, 1977.
- Vaupel, D. B. and Martin, W. R.: A comparison of the effects of 4-bromo-2,5dimethoxyamphetamine, 3,4,5-trimethoxyamphetamine, para-methoxyamphetamine, *d*-amphetamine and LSD in the nontolerant and LSD tolerant chronic spinal dog. *Pharmacologist* 19: 230, 1977.
- Vaupel, D. B. and Martin, W. R.: LSD-like hallucinogens in the dog: Validation studies with mescaline, psilocin and dimethyltryptamine. *Fed. Proc.* 37: 273, 1978.
- Cone, E. J., Buchwald, W. F., Gorodetzky, C. W. and Vaupel, D. B.: Evidence for toxic precursors in illicit phencyclidine preparations. *Fed. Proc.* 38: 435, 1979.
- Vaupel, D. B. and Jasinski, D. R.: Acute single dose effects of phencyclidine in the dog. *Fed. Proc.* 38: 435, 1979.
- Vaupel, D. B.: Phencyclidine studies: Single dose effects in the spinal dog, suppression of food intake in the intact dog, and potency estimates of 12 analogues in the mouse. Appendix C(7), Final Report, Technical Review on the Chemistry and Pharmacology of PCP and its Analogues, National Institute on Drug Abuse, Rockville, MD, March 14-15, 1979.
- Shannon, H. E., Vaupel, D. B., Risner, M. E. and Cone, E. J.: Pharmacology of phenethylamine trace amines in the dog--discussion. *Psychopharmacol. Bull.* 16: 54-55, 1980.
- Cone, E. J., Vaupel, D. B. and Yousefnejad, D.: Metabolism of phencyclidine (PCP) and relative potencies of two hydroxylated metabolites. *Fed. Proc.* 39: 302, 1980.

Jasinski, D. R., Shannon, H. E., Vaupel, D. B., Cone, E. J., Risner, M. E., McQuinn, R. L., Su, T. P. and Pickworth, W. B.: Interdisciplinary studies on phencyclidine at the Addiction Research Center, Lexington, Ky. *Psychopharmacol. Bull.* 16: 79-81, 1980.

Vaupel, D. B.: Failure of naltrexone (NTX) to antagonize phencyclidine (PCP) and the opioid SKF 10047 in the dog. *Fed. Proc.* 41: 1333, 1982.

Vaupel, D. B.: Lack of pharmacologic specificity and selectivity between the d(+) and l(-) isomers of N-allylnormetazocine (NANM). *Pharmacologist* 24: 117, 1982.

Vaupel, D. B.: Phencyclidine studies in the dog: Pharmacology of PCP, similarity to the opioid NANM (N-allylnormetazocine or SKF 10047) and profiles of eight analogues abused by man. Presented, Joint French-U.S. Seminar on the Chemistry, Pharmacology, Toxicology, Therapy and Drug Abuse Aspects of Arylcyclohexylamines, VVF LePonant LaGrand Motte, Montpellier, France, Sept. 21-24, 1982.

Vaupel, D. B.: Evidence in the chronic spinal dog on the abuse liability of eight phencyclidine analogues. *Fed. Proc.* 42: 1017, 1983.

Vaupel, D. B.: Additive and nonadditive effects of pentazocine (P) and tripeleminamine (T) combinations in the dog. *Fed. Proc.* 43:746, 1984.

Vaupel, D. B.: Stereospecific effects of the l-isomer of Ketocyclazocine (KC) in the dog. *The Pharmacologist* 26:161, 1984.

Vaupel, D.B., Cone, E.J., and Johnson, R.E.: An enkephalin-like pentapeptide (BW942C) with partial kappa agonist activity. Submitted to Society for Neuroscience